Geographical Variations in the Effectiveness and Safety of Abbreviated or Standard Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients at High Bleeding Risk

Abstract

In high bleeding risk (HBR) patients, noninferiority of 1month dual antiplatelet therapy (APT) to treatment continuation for double dagger 2 additional months for the occurrence of net and major adverse clinical events after drug-eluting stent implantation was shown in the Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Ste nt Implantation With an Abbreviated Versus Prolonged DAPT Regimen (MASTER DAPT) trial.1 1 A significant fi cant reduction in bleeding was also noted. However, whether these treatment effects of APT are consistent across geographical regions remains uncertain. In the present analyses, the effects of abbreviated or standard APT on the 1-year occurrence of net and major adverse clinical events and bleeding were consistent across geographical regions (Europe, East Asia, and others). [Clinical Trial Registration: https://www.clinicaltrials.gov. Unique identifier: fi er: NCT03023020].